First Al Minya

Researchers are evaluating the 24-month clinical and radiographic outcomes of two different revascularization treatments for asymptomatic necrotic immature permanent maxillary incisors. This randomized clinical trial compares a single-visit protocol to a multiple-visit protocol to understand how each approach affects healing and tooth condition over time. Participants will receive either the single-visit revascularization procedure or the multiple-visit revascularization procedure, both aimed at treating the affected immature permanent incisor. The study will follow these treatments closely to assess differences in outcomes related to healing and tooth preservation. During the 24-month study period, researchers will monitor participants for signs of pain and other clinical or radiographic changes. The number of participants experiencing pain after treatment will be recorded from enrollment through the end of treatment at 24 months. Regular assessments and imaging will help track treatment effectiveness and safety throughout the study.

Researchers are evaluating a new method to manage a complication called Descemet's Membrane detachment that can occur after cataract surgery. The study aims to measure the effectiveness of this technique in restoring the membrane's proper position within the first week after surgery. This condition affects patients aged 50 to 70 years old who develop the detachment within the first week following their cataract operation. Participants will be divided into two groups: one group will receive a direct air injection inside the eye chamber, while the other group will have the eye chamber deflated before the air injection. Both procedures are designed to help reposition the detached Descemet's Membrane. These treatments will be compared to see which approach better achieves complete anatomical reduction. During the study, patients will be closely monitored, including imaging with anterior segment optical coherence tomography (ASOCT) to assess the membrane's position one week after treatment. Researchers will track the rate of complete membrane reattachment as the main outcome. The study focuses on the short-term effectiveness and safety of these procedures in managing this post-surgical complication.

Researchers are evaluating the protective effects of Alpha-Lipoic Acid (ALA) against kidney damage caused by cisplatin chemotherapy in cancer patients. This Phase 2, randomized, controlled, open-label study compares patients receiving standard cisplatin treatment with or without ALA to assess changes in kidney function. The study focuses on patients with solid tumors who are planned to receive cisplatin at doses starting from 60 mg/m2 per cycle. Participants are randomly assigned to receive either oral Alpha-Lipoic Acid alongside their cisplatin chemotherapy or cisplatin chemotherapy alone. The treatment cycles occur every 21 to 28 days or may be fractionated. The trial uses a parallel group design and does not mask the treatment allocation. Throughout the study, patients' kidney function is monitored weekly for up to six weeks by measuring serum creatinine and creatinine clearance. Researchers will compare these measurements between groups to evaluate the kidney-protective effects of ALA. Participants must have good performance status and normal or near-normal kidney function at the start. The total study involvement includes regular assessments to ensure safety and to track kidney health during chemotherapy.

Anastomotic leakage (AL) is a serious complication that can occur after colorectal surgery, with rates ranging from 2% to 30%. This research aims to identify and measure risk factors that contribute to AL, understand its frequency and effects on patient outcomes, and create a predictive model. The study will enroll about 430 patients undergoing colorectal resection with anastomosis between August 2025 and August 2026 at a single center to reduce variability. Participants will be patients having elective or emergency colorectal surgery with primary anastomosis, including types like ileocolic, colocolic, colorectal, or coloanal. The study will monitor risk factors before, during, and after surgery, including patient demographics, health status, surgical details, and postoperative care. Anastomotic leakage will be defined and graded using established criteria based on symptoms, radiological findings, and the need for interventions or reoperation. During the study, patients will be assessed for signs of leakage through clinical evaluations, imaging, and laboratory tests such as inflammatory markers in serum and drain fluid. Data will be collected from medical records and follow-up visits. Researchers will analyze this information to determine risk factors and develop a model predicting AL. The main outcome measured is the occurrence of anastomotic leakage within 30 days after surgery, with safety and recovery closely monitored throughout the study period.

Researchers are investigating the effects of adding magnesium sulfate to atracurium as adjuvants to local anesthetic during peribulbar anesthesia for cataract surgery. The study focuses on how this combination influences the onset and duration of akinesia, which is the lack of movement in the eyeball and eyelid. Peribulbar anesthesia is preferred for eye surgeries because it is safer and has fewer serious complications compared to other regional blocks. Participants receive peribulbar anesthesia with local anesthetic, and the study compares the use of atracurium alone versus atracurium combined with magnesium sulfate. Magnesium sulfate acts as an NMDA antagonist and calcium channel blocker, potentially enhancing the anesthetic effect and improving anesthesia quality. Atracurium is a non-depolarizing neuromuscular blocker known to speed up akinesia onset and improve anesthesia without adverse effects. During the study, participants undergo cataract surgery with either anesthetic approach. Researchers assess the quality of the nerve block at baseline and monitor the onset and duration of akinesia. They also evaluate safety and anesthesia effectiveness throughout the procedure. The study includes adults aged 20 to 80 years undergoing elective cataract surgery, with follow-up on anesthesia performance and any side effects.

Researchers are evaluating whether neoadjuvant chemoradiotherapy can improve overall survival compared to immediate surgery in patients with resectable and borderline resectable pancreatic cancer. Pancreatic cancer has poor treatment outcomes, and while surgery offers relatively better results for resectable cases, the 5-year survival rate remains low at about 20%. Neoadjuvant therapy may allow more patients to receive chemotherapy, improve surgical margin clearance, and identify patients whose disease progresses rapidly to avoid unnecessary surgery. The study compares two treatment approaches: one group receives immediate surgery followed by adjuvant chemotherapy, while the other group undergoes neoadjuvant chemotherapy before surgery. Both groups then receive adjuvant chemotherapy after surgery. The goal is to see which approach leads to better survival outcomes. Participants will be monitored for overall survival up to one year after the procedure. The study involves imaging with CT scans using pancreatic protocols and vascular mapping, as well as biopsy confirmation before treatment. Researchers will assess the success of surgery, survival rates, and the impact of treatment timing on outcomes, with careful selection based on tumor location and resectability criteria.

Post-dural puncture headache (PDPH) is a common and painful complication that can occur after spinal anesthesia in pregnant women having cesarean sections. It happens when cerebrospinal fluid leaks through the puncture site, causing tension on pain-sensitive areas in the brain and resulting in severe headache. This trial evaluates treatments for PDPH, focusing on the effects of nebulized neostigmine/atropine compared to nebulized lidocaine, aiming to improve headache relief following cesarean delivery under spinal anesthesia. The study is an early phase 1 randomized clinical trial. Participants are divided into treatment groups, including one that receives nebulized lidocaine with saline (4 ml total volume, containing 60 mg lidocaine). The trial compares this with nebulized neostigmine/atropine, which may help by causing cerebral vasoconstriction and blocking pain signals through different mechanisms. These treatments are given to women who develop acute PDPH after elective cesarean sections performed under spinal anesthesia. During the study, researchers will assess headache pain using a visual analog scale (VAS) three days after treatment. They will monitor participants for headache relief and any side effects. Women aged 18 to 35 years who have a moderate to severe postpartum headache following cesarean section with spinal anesthesia are eligible. Participation includes follow-up for at least three days to evaluate treatment effectiveness and safety.

This research aims to compare the effects of Concerned Growth Factor and Mineral Trioxide Aggregate in treating mature permanent molars of children diagnosed with irreversible pulpitis. The study focuses on children aged 9 to 16 years and evaluates the management approaches for this dental condition over an 18-month period. Participants will receive treatment either with Concerned Growth Factor or Mineral Trioxide Aggregate applied to the affected mature permanent molars. These treatments will be studied to assess their clinical and radiographic outcomes in managing irreversible pulpitis. Throughout the 12 months following treatment, participants will undergo clinical evaluations including visual analogue scale assessments, electrical pulp testing, sensitivity tests with hot and cold stimuli, and percussion tests on the treated teeth. Radiographic exams will also be performed to measure the success of each treatment method in managing the condition.

This clinical trial focuses on men with erectile dysfunction (ED) who have not responded to PDE5 inhibitors. It aims to evaluate whether combining daily tadalafil 5 mg with on-demand sildenafil 100 mg improves erectile function better than on-demand sildenafil alone. The study also assesses the safety and tolerability of this combination therapy in this patient group. Participants will be randomly assigned to one of two groups: one receiving daily tadalafil 5 mg plus on-demand sildenafil 100 mg, and the other receiving daily placebo plus on-demand sildenafil 100 mg. The treatment period lasts 12 weeks, during which participants take their assigned medications as directed. Throughout the study, participants will undergo baseline assessments including medical history, physical exam, and lab tests. Follow-up evaluations at 4, 8, and 12 weeks include questionnaires measuring erectile function, assessments of erection hardness, and monitoring for any adverse effects. The main outcome measured is the change in erectile function from the start through 12 weeks of treatment.

Mesh prosthesis was introduced to hernial surgery as a magic solution for any inguinal hernia, and it has significant advantages (Simplicity of the procedure, Mesh is cheap, and has a low recurrence rate). Still, mesh induces fibrosis that can lead to stiffness and foreign body sensation, which become a source of agony for the patient. Mesh infection is one of the serious complications that can lead to the removal of the mesh and long-term terms morbidity from Lichtenstein hernia repairs, such as Vas entrapment and Chronic groin pain. Desarda technique requires no extensive dissection or only suturing; no mesh is needed, and it is easy to learn. It is still ferrated and determined the optimum procedure to treat an inguinal hernia. It is a straightforward operation that avoids the risks of mesh implantation, has a low recurrence rate, and can be done by non-consultant staff.